• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型NR2B选择性N-甲基-D-天冬氨酸受体拮抗剂设计的计算机模拟见解:定量构效关系建模、药物代谢动力学-毒性预测、分子对接及分子动力学研究

In silico insights into the design of novel NR2B-selective NMDA receptor antagonists: QSAR modeling, ADME-toxicity predictions, molecular docking, and molecular dynamics investigations.

作者信息

El Fadili Mohamed, Er-Rajy Mohammed, Mujwar Somdutt, Ajala Abduljelil, Bouzammit Rachid, Kara Mohammed, Abuelizz Hatem A, Er-Rahmani Sara, Elhallaoui Menana

机构信息

LIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, 30000, Morocco.

Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.

出版信息

BMC Chem. 2024 Jul 31;18(1):142. doi: 10.1186/s13065-024-01248-6.

DOI:10.1186/s13065-024-01248-6
PMID:39085870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11293250/
Abstract

Based on a structural family of thirty-two NR2B-selective N-Methyl-D-Aspartate receptor (NMDAR) antagonists, two phenylpiperazine derivatives labeled C37 and C39 were conceived thanks to molecular modeling techniques, as novel NMDAR inhibitors exhibiting the highest analgesic activities (of pIC order) against neuropathic pain, with excellent ADME-toxicity profiles, and good levels of molecular stability towards the targeted protein of NMDA receptor. Initially, the quantitative structure-activity relationships (QSARs) models were developed using multiple linear regression (MLR), partial least square regression (PLSR), multiple non-linear regression (MNLR), and artificial neural network (ANN) techniques, revealing that analgesic activity was strongly correlated with dipole moment, octanol/water partition coefficient, Oxygen mass percentage, electronegativity, and energy of the lowest unoccupied molecular orbital, whose the correlation coefficients of generated models were: 0.860, 0.758, 0.885 and 0.977, respectively. The predictive capacity of each model was evaluated by an external validation with correlation coefficients of 0.703, 0.851, 0.778, and 0.981 respectively, followed by a cross-validation technique with the leave-one-out procedure (CVLOO) with Q of 0.785, more than Y-randomization test, and applicability domain (AD), in addition to Fisher's and Student's statistical tests. Thereafter, ten novel molecules were designed based on MLR QSAR model, then predicted with their ADME-Toxicity profiles and subsequently examined for their similarity to the drug candidates. Finally, two of the most active compounds (C37 and C39) were chosen for molecular docking and molecular dynamics (MD) investigations during 100 ns of MD simulation time in complex with the targeted protein of NMDA receptor (5EWJ.pdb).

摘要

基于一个由32种NR2B选择性N - 甲基 - D - 天冬氨酸受体(NMDAR)拮抗剂组成的结构家族,借助分子建模技术构思出了两种标记为C37和C39的苯基哌嗪衍生物,作为新型NMDAR抑制剂,它们对神经性疼痛表现出最高的镇痛活性(pIC级),具有优异的药代动力学 - 毒性特征,并且对NMDA受体的靶向蛋白具有良好的分子稳定性。最初,使用多元线性回归(MLR)、偏最小二乘回归(PLSR)、多元非线性回归(MNLR)和人工神经网络(ANN)技术建立了定量构效关系(QSAR)模型,结果表明镇痛活性与偶极矩、辛醇/水分配系数、氧质量百分比、电负性以及最低未占分子轨道能量密切相关,所生成模型的相关系数分别为:0.860、0.758、0.885和0.977。通过外部验证评估每个模型的预测能力,相关系数分别为0.703、0.851、0.778和0.981,随后采用留一法(CVLOO)交叉验证技术,Q值为0.785,超过Y随机化检验和适用域(AD),此外还进行了费舍尔和学生统计检验。此后,基于MLR QSAR模型设计了10种新型分子,然后预测它们的药代动力学 - 毒性特征,并随后检查它们与候选药物的相似性。最后,选择两种活性最高的化合物(C37和C39)在与NMDA受体的靶向蛋白(5EWJ.pdb)复合的情况下进行100 ns的分子动力学(MD)模拟时间的分子对接和分子动力学(MD)研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/9ebb02550eaf/13065_2024_1248_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a534019d6e61/13065_2024_1248_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a0da801bf661/13065_2024_1248_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/8fc45109a84c/13065_2024_1248_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/8ab676846acb/13065_2024_1248_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/bfc9a2717235/13065_2024_1248_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/d4a204ab9929/13065_2024_1248_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/0bc94be31e2c/13065_2024_1248_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a8cf30bf1d99/13065_2024_1248_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/224b551c707e/13065_2024_1248_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/1299726ba853/13065_2024_1248_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/3a4b5ee484ec/13065_2024_1248_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/9f0689393db3/13065_2024_1248_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/435022a6eedf/13065_2024_1248_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/9ebb02550eaf/13065_2024_1248_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a534019d6e61/13065_2024_1248_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a0da801bf661/13065_2024_1248_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/8fc45109a84c/13065_2024_1248_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/8ab676846acb/13065_2024_1248_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/bfc9a2717235/13065_2024_1248_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/d4a204ab9929/13065_2024_1248_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/0bc94be31e2c/13065_2024_1248_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/a8cf30bf1d99/13065_2024_1248_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/224b551c707e/13065_2024_1248_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/1299726ba853/13065_2024_1248_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/3a4b5ee484ec/13065_2024_1248_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/9f0689393db3/13065_2024_1248_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/435022a6eedf/13065_2024_1248_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cc4/11293250/9ebb02550eaf/13065_2024_1248_Fig14_HTML.jpg

相似文献

1
In silico insights into the design of novel NR2B-selective NMDA receptor antagonists: QSAR modeling, ADME-toxicity predictions, molecular docking, and molecular dynamics investigations.新型NR2B选择性N-甲基-D-天冬氨酸受体拮抗剂设计的计算机模拟见解:定量构效关系建模、药物代谢动力学-毒性预测、分子对接及分子动力学研究
BMC Chem. 2024 Jul 31;18(1):142. doi: 10.1186/s13065-024-01248-6.
2
A combined approaches of 2D-QSAR, molecular docking, molecular dynamics and ADMET prediction of anti-cancer inhibitor activity for actinonin derivatives.二维定量构效关系(2D-QSAR)、分子对接、分子动力学和 ADMET 预测相结合的方法,研究了肌肽衍生物的抗癌抑制剂活性。
J Biomol Struct Dyn. 2024 Jan-Feb;42(1):119-133. doi: 10.1080/07391102.2023.2192801. Epub 2023 Mar 30.
3
Cyclohexane-1,3-dione Derivatives as Future Therapeutic Agents for NSCLC: QSAR Modeling, In Silico ADME-Tox Properties, and Structure-Based Drug Designing Approach.环己烷-1,3-二酮衍生物作为非小细胞肺癌的未来治疗药物:定量构效关系建模、计算机辅助药物代谢动力学-毒理学性质研究及基于结构的药物设计方法
ACS Omega. 2023 Jan 19;8(4):4294-4319. doi: 10.1021/acsomega.2c07585. eCollection 2023 Jan 31.
4
Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones.基于分子相似性原理的抗HIV吲哚基芳基砜类线性和非线性预测QSAR模型的构建及其外部验证
J Enzyme Inhib Med Chem. 2008 Dec;23(6):980-95. doi: 10.1080/14756360701811379.
5
Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches.利用基于定量构效关系的虚拟筛选、分子对接、分子动力学模拟和分子力学广义 Born 表面面积方法鉴定有效的醛糖还原酶抑制剂作为抗糖尿病(降血糖)药物。
Saudi Pharm J. 2022 Jun;30(6):693-710. doi: 10.1016/j.jsps.2022.04.003. Epub 2022 Apr 7.
6
An in-silico investigation based on molecular simulations of novel and potential brain-penetrant GluN2B NMDA receptor antagonists as anti-stroke therapeutic agents.基于分子模拟的新型潜在可穿透血脑屏障的 GluN2B NMDA 受体拮抗剂作为抗中风治疗剂的计算机研究
J Biomol Struct Dyn. 2024 Aug;42(12):6174-6188. doi: 10.1080/07391102.2023.2232024. Epub 2023 Jul 10.
7
Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques.通过结合三维定量构效关系、分子对接、药物代谢动力学/药物毒性预测及分子动力学模拟技术对吡咯烷衍生物作为新型髓样细胞白血病-1抑制剂的分子建模研究
J Biomol Struct Dyn. 2023;41(23):13798-13814. doi: 10.1080/07391102.2023.2183032. Epub 2023 Feb 25.
8
Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.通过 QSAR 和分子建模研究设计潜在的抗肿瘤 PARP-1 抑制剂。
Mol Divers. 2021 Feb;25(1):263-277. doi: 10.1007/s11030-020-10063-9. Epub 2020 Mar 5.
9
A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.基于药效团模型、QSAR 研究、分子对接和计算机 ADME/Tox 预测的 4-芳基硫代和 4-芳氧基-3-碘吡啶-2(1H)-酮类似物的综合方法,以鉴定潜在的逆转录酶抑制剂:抗 HIV 药物。
Med Chem. 2022;18(1):51-87. doi: 10.2174/1573406417666201214100822.
10
Design of novel isoxazole derivatives as tubulin inhibitors using computer-aided techniques: QSAR modeling, ADMETox, molecular docking, molecular dynamics, biological efficacy, and retrosynthesis.利用计算机辅助技术设计新型异恶唑衍生物作为微管蛋白抑制剂:定量构效关系建模、药物代谢动力学/药物毒性预测、分子对接、分子动力学、生物活性及逆合成分析
J Biomol Struct Dyn. 2025 Jul;43(10):4997-5008. doi: 10.1080/07391102.2024.2306493. Epub 2024 Feb 14.

引用本文的文献

1
design of novel dihydropteridone derivatives with oxadiazoles as potent inhibitors of MCF-7 breast cancer cells.以恶二唑为有效MCF-7乳腺癌细胞抑制剂的新型二氢蝶啶酮衍生物的设计
Front Chem. 2025 Jul 28;13:1590593. doi: 10.3389/fchem.2025.1590593. eCollection 2025.
2
Identification of Novel Scaffolds Against GSK-3β for Targeting Alzheimer's Disease Through Molecular Modeling Techniques.通过分子建模技术鉴定针对糖原合成酶激酶-3β的新型支架以治疗阿尔茨海默病
Cell Mol Neurobiol. 2025 Aug 4;45(1):77. doi: 10.1007/s10571-025-01568-8.
3
Design of novel pyrazole and benzofuran-based derivatives as potent acetylcholinesterase inhibitors for Alzheimer's disease management.

本文引用的文献

1
New Triazole-Isoxazole Hybrids as Antibacterial Agents: Design, Synthesis, Characterization, In Vitro, and In Silico Studies.新型三唑-异噁唑杂合体作为抗菌剂:设计、合成、表征、体外和计算研究。
Molecules. 2024 May 26;29(11):2510. doi: 10.3390/molecules29112510.
2
Comprehensive analysis of different solvent extracts of Ferula communis L. fruit reveals phenolic compounds and their biological properties via in vitro and in silico assays.综合分析阿魏属植物果实的不同溶剂提取物,通过体外和计算方法揭示其酚类化合物及其生物特性。
Sci Rep. 2024 Apr 9;14(1):8325. doi: 10.1038/s41598-024-59087-3.
3
Phytochemical, Antioxidant Activity, and Toxicity of Wild Medicinal Plant of Extracts, and Approaches.
新型吡唑和苯并呋喃基衍生物的设计,作为用于阿尔茨海默病治疗的强效乙酰胆碱酯酶抑制剂。
Front Chem. 2025 May 22;13:1614462. doi: 10.3389/fchem.2025.1614462. eCollection 2025.
4
Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer's disease treatment.乙酰胆碱酯酶抑制的创新方法:有效治疗阿尔茨海默病的途径。
Mol Divers. 2025 Mar 24. doi: 10.1007/s11030-025-11170-1.
5
leaf extract: antioxidant capacity, UHPLC-MS/MS analysis, and and toxicity investigations.叶提取物:抗氧化能力、超高效液相色谱-串联质谱分析及毒性研究
Front Chem. 2025 Jan 24;12:1485463. doi: 10.3389/fchem.2024.1485463. eCollection 2024.
6
Therapeutic exploration potential of adenosine receptor antagonists through pharmacophore ligand-based modelling and pharmacokinetics studies against Parkinson disease.通过基于药效团配体的建模和针对帕金森病的药代动力学研究探索腺苷受体拮抗剂的治疗潜力。
In Silico Pharmacol. 2025 Jan 25;13(1):17. doi: 10.1007/s40203-025-00305-9. eCollection 2025.
野生药用植物提取物的植物化学成分、抗氧化活性及毒性与方法
ACS Omega. 2024 Feb 9;9(8):9236-9246. doi: 10.1021/acsomega.3c08314. eCollection 2024 Feb 27.
4
Dysphania ambrosioides (L.) Mosyakin and Clemants: bridging traditional knowledge, photochemistry, preclinical investigations, and toxicological validation for health benefits.唇形科植物 Ambrosia ambrosioides (L.) Mosyakin 和 Clemants:连接传统知识、光化学、临床前研究和毒理学验证,以获得健康益处。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):969-1001. doi: 10.1007/s00210-023-02658-4. Epub 2023 Aug 8.
5
An in-silico investigation based on molecular simulations of novel and potential brain-penetrant GluN2B NMDA receptor antagonists as anti-stroke therapeutic agents.基于分子模拟的新型潜在可穿透血脑屏障的 GluN2B NMDA 受体拮抗剂作为抗中风治疗剂的计算机研究
J Biomol Struct Dyn. 2024 Aug;42(12):6174-6188. doi: 10.1080/07391102.2023.2232024. Epub 2023 Jul 10.
6
QSAR, ADME-Tox, molecular docking and molecular dynamics simulations of novel selective glycine transporter type 1 inhibitors with memory enhancing properties.具有记忆增强特性的新型选择性甘氨酸转运体1抑制剂的定量构效关系、药物代谢动力学-药物毒性、分子对接和分子动力学模拟
Heliyon. 2023 Feb 13;9(2):e13706. doi: 10.1016/j.heliyon.2023.e13706. eCollection 2023 Feb.
7
Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular docking and molecular dynamics simulation.基于 3D QSAR、分子对接和分子动力学模拟设计新型靶向 TRKs 的抗癌药物。
J Biomol Struct Dyn. 2023;41(21):11657-11670. doi: 10.1080/07391102.2023.2170471. Epub 2023 Jan 25.
8
Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer's: Design, Synthesis, and Biological Evaluation.针对阿尔茨海默病中乙酰胆碱酯酶的茚衍生酰肼类化合物:设计、合成及生物学评价
Pharmaceutics. 2022 Dec 28;15(1):94. doi: 10.3390/pharmaceutics15010094.
9
docking and molecular dynamic introspective study of multiple targets of AChE with Rivastigmine and NMDA receptors with Riluzole for Alzheimer's disease.用卡巴拉汀对乙酰胆碱酯酶多个靶点以及用利鲁唑对N-甲基-D-天冬氨酸受体进行对接和分子动力学内省研究以治疗阿尔茨海默病
J Biomol Struct Dyn. 2023;41(22):12620-12631. doi: 10.1080/07391102.2023.2167119. Epub 2023 Jan 16.
10
Computational Design, Synthesis, and Pharmacological Evaluation of Naproxen-Guaiacol Chimera for Gastro-Sparing Anti-Inflammatory Response by Selective COX2 Inhibition.通过选择性 COX2 抑制作用,设计、合成并评价萘普生-愈创木酚偶联物用于胃肠道抗炎反应的计算方法。
Molecules. 2022 Oct 14;27(20):6905. doi: 10.3390/molecules27206905.